Human IFN-gamma Antibody Best Seller
R&D Systems, part of Bio-Techne | Catalog # AF-285-NA
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human, Primate - Macaca mulatta (Rhesus Macaque), Xenograft
Applications
Validated:
Immunocytochemistry, Neutralization, Western Blot
Cited:
CAR-T (IHC-Fr), Immunohistochemistry, Immunohistochemistry-Paraffin, Neutralization, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Goat IgG
Product Specifications
Immunogen
E. coli-derived recombinant human IFN-gamma
Met1-Gln144
Accession # Q14609
Met1-Gln144
Accession # Q14609
Specificity
Detects human IFN-gamma in direct ELISAs and Western blots.
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human IFN-gamma Antibody
IFN-gamma Inhibition of EMCV-induced Cytopathy and Neutralization by Human IFN-gamma Antibody.
Recombinant Human IFN-gamma (285-IF) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HeLa human cervical epithelial carcinoma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of EMCV activity elicited by Recombinant Human IFN-gamma (5 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IFN-gamma Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-285-NA). The ND50 is typically 0.0300 ‑ 0.300 µg/mL.IFN-gamma in Human PBMCs.
IFN-gamma was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) stimulated with PMA and ionomycin using 10 µg/mL Goat Anti-Human IFN-gamma Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-285-NA) for 3 hours at room temperature. Cells were stained with the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red); (NL001) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Non-adherent Cells.Applications for Human IFN-gamma Antibody
Application
Recommended Usage
Immunocytochemistry
5-15 µg/mL
Sample: Immersion fixed human peripheral blood mononuclear cells (PBMCs) stimulated with PMA and ionomycin.
Sample: Immersion fixed human peripheral blood mononuclear cells (PBMCs) stimulated with PMA and ionomycin.
Western Blot
0.1 µg/mL
Sample: Recombinant Human IFN-gamma (Catalog # 285-IF)
Sample: Recombinant Human IFN-gamma (Catalog # 285-IF)
Neutralization
Measured by its ability to neutralize IFN-gamma inhibition of EMCV-induced cytopathy in the HeLa human cervical epithelial carcinoma cell line. Meager, A. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 129. The Neutralization Dose (ND50) is typically 0.0300 - 0.300 µg/mL in the presence of 5.00 ng/mL Recombinant Human IFN-gamma.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Reviewed Applications
Read 3 reviews rated 4.3 using AF-285-NA in the following applications:
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IFN-gamma
Long Name
Interferon gamma
Alternate Names
IFG, IFI, IFNG, IFNgamma
Entrez Gene IDs
Gene Symbol
IFNG
UniProt
Additional IFN-gamma Products
Product Documents for Human IFN-gamma Antibody
Product Specific Notices for Human IFN-gamma Antibody
For research use only
Loading...
Loading...
Loading...
Loading...